XTX Topco Ltd Acquires Shares of 13,304 TG Therapeutics, Inc. (NASDAQ:TGTX)

XTX Topco Ltd bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,304 shares of the biopharmaceutical company's stock, valued at approximately $400,000.

Several other large investors also recently bought and sold shares of TGTX. Vanguard Group Inc. boosted its stake in shares of TG Therapeutics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after acquiring an additional 209,190 shares during the last quarter. Clearbridge Investments LLC acquired a new stake in TG Therapeutics in the 4th quarter worth about $55,237,000. Charles Schwab Investment Management Inc. boosted its stake in TG Therapeutics by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock worth $38,212,000 after buying an additional 84,904 shares during the last quarter. Invesco Ltd. boosted its stake in TG Therapeutics by 1.2% in the 4th quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company's stock worth $27,985,000 after buying an additional 10,989 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in TG Therapeutics by 10.5% in the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company's stock worth $27,797,000 after buying an additional 87,679 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Analysts Set New Price Targets

TGTX has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Stock Up 1.7 %

Shares of NASDAQ:TGTX traded up $0.70 during mid-day trading on Monday, hitting $42.03. 1,784,031 shares of the company traded hands, compared to its average volume of 3,080,916. The firm has a market cap of $6.67 billion, a P/E ratio of -420.26 and a beta of 2.14. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The firm's 50 day simple moving average is $37.40 and its 200 day simple moving average is $32.73.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.